Literature DB >> 27450645

Fibroblast growth factor 23 and soluble Klotho in patients with autosomal dominant polycystic kidney disease.

Kenichi Akiyama1, Toshio Mochizuki1, Hiroshi Kataoka1, Ken Tsuchiya1, Kosaku Nitta1.   

Abstract

AIM: This study aimed to examine the roles of fibroblast growth factor 23 (FGF23) and soluble Klotho in phosphate metabolism in autosomal-dominant polycystic kidney disease (ADPKD) patients.
METHODS: We measured these two factors and phosphate metabolism parameters in 80 patients with ADPKD and 53 patients with non-diabetic chronic kidney disease (CKD).
RESULTS: The mean serum FGF23 level in the ADPKD group was significantly (twofold) higher than in the non-diabetic CKD patients, but the mean soluble Klotho level in the ADPKD group was significantly lower in the non-diabetic CKD group. The mean serum phosphate levels of the two groups were similar. The estimated glomerular filtration rate (eGFR) was approximately 45 mL/min per 1.73 m2 in both groups, and their serum vitamin D metabolite levels were in the normal range.
CONCLUSION: The serum FGF23 levels were significantly higher and soluble Klotho levels significantly lower in the ADPKD group than in the non-diabetic CKD group matched for eGFR, and these findings may be associated with resistance of renal phosphate excretion.
© 2016 Asian Pacific Society of Nephrology.

Entities:  

Keywords:  fibroblast growth factor 23; klotho; parathyroid hormone; phosphate; polycystic kidney disease

Mesh:

Substances:

Year:  2017        PMID: 27450645     DOI: 10.1111/nep.12862

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  2 in total

1.  A decreased soluble Klotho level with normal eGFR, FGF23, serum phosphate, and FEP in an ADPKD patient with enlarged kidneys due to multiple cysts.

Authors:  Takahiro Kanai; Kazuhiro Shiizaki; Hiroyuki Betsui; Jun Aoyagi; Takanori Yamagata
Journal:  CEN Case Rep       Date:  2018-05-16

Review 2.  New treatment paradigms for ADPKD: moving towards precision medicine.

Authors:  Matthew B Lanktree; Arlene B Chapman
Journal:  Nat Rev Nephrol       Date:  2017-10-09       Impact factor: 28.314

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.